VYNE — Vyne Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$28.56
+$0.00 (+0.00%)
Vyne Therapeutics Inc (VYNE) is a biotechnology company listed on NASDAQ. It is led by David T. Domzalski, based in P.O. BOX 125, Stewartsville, NJ, United States, 08886, with about 10 employees. VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
Latest reported VYNE revenue for 2025-06-30 was $69.0K. Net income was -$5.8M. Revenue was down 65.8% from 2025-03-31 to 2025-06-30. VYNE currently screens at market cap $21.1M.
Use this VYNE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VYNE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VYNE SEC filings page. Lician reads the product cache first so this HTML stays unique to Vyne Therapeutics Inc even when a live quote feed is slow.
About Vyne Therapeutics Inc
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
VYNE Key Statistics
Market Cap
$21.07M
Volume
93,256
Previous Close
$28.56
Day Range
$23.37 – $28.56
P/B Ratio
0.86
EPS
-$0.93
Revenue
$501.00K
Net Income
-$39.83M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+18.2%
Profit Margin
-7950.9%
Employees
10
VYNE Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $501.00K | $424.00K | $477.00K | $931.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$39.83M | -$28.45M | -$23.21M | -$73.33M |
| EPS (Diluted) | -$0.93 | -$2.78 | -$7.28 | -$25.64 |
Total Assets
$66.91M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$19.93M
Operating Cash Flow
-$33.97M
Free Cash Flow
$0.00
Vyne Therapeutics Inc Company Information
- CEO, President & Director
- David T. Domzalski
- Headquarters
- P.O. BOX 125, Stewartsville, NJ, United States, 08886
- Website
- vynetherapeutics.com
- Phone
- 800 775 7936
- IPO / Founded
- 2018-01-25
- Sector
- Healthcare
- Industry
- Biotechnology